A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors
Trial Parameters
Brief Summary
There is a high medical need to improve treatment outcome for high-grade and low-grade glioma since no curative treatment is available. To achieve this goal, a broader understanding is needed of the causes of inter-and intratumoral heterogeneity; glioma dedifferentiation and invasion; the major determinants of malignancy and treatment failure in glioma patients. Patient-derived organoid (PDOs) of high-grade gliomas and low-grade gliomas will be used to identify the mechanisms that underlie this malignant behaviour and treatment resistance. This insight may be used to develop patient avatars to simultaneously test multiple new treatment modalities that are predictive for survival and quality of life of glioma patients.
Eligibility Criteria
Inclusion Criteria: * MRI diagnosis of low grade glioma (LGG) or high grade glioma (HGG) * Age 18 years or older * Patient is eligible for a resection of the tumor Exclusion Criteria: * Contra-inidication for neurosurgical resection of the tumor. * Incapacitated patient, unable to give informed consent.